In the News
WCMC researchers, along with an international team, discovered a way to cure cardiac disease in mice with a fatal muscle disorder that usually strikes teenagers. Two-thirds of patients with the disease, Friedreich's ataxia, die of failing hearts in their early 30s.
Metabolon, pioneers in the emerging field of metabolomics-driven biomarker discovery, announced the launch of DiscoveryHD4™, the company’s fourth-generation metabolomics platform designed to empower the company’s TrueVision™, mVision™, and mView™ research and biomarker discovery offerings as well as its diagnostic product development pipeline.
Thorne Research, manufacturer of pure, highly absorbable nutritional supplements, launched NiaCel™, a supplement that supports endurance, energy, and healthy aging, featuring the ingredient NIAGEN™, which is based on Cornell technology licensed by ChromaDex Corp.
Axium Nanofibers, a material science company commercializing a novel class of nanomaterials for a broad range of applications including energy storage, has partnered with AZ Electronic Materials, producers of high-purity specialty chemical materials used in the manufacturing of semiconductors, flat panel displays, and LEDs, to co-sponsor research at Cornell with the goal of developing nanomaterials into commercial products for the energy storage market in the next 18-24 months.
ADC, an engineering and scientific consulting firm that provides devices, integrated systems and high-precision components and instruments to commercial, academic, and government agencies worldwide, introduced the HPC-201, a high-pressure cryocooler that prepares proteins for X-ray crystallography.
PacBio, developers of products that enable targeted sequencing to more comprehensively characterize genetic variations, released a software upgrade for its Single Molecule, Real-Time (SMRT) DNA Sequencing platform to support full-length transcript sequencing and human leukocyte antigen (HLA) haplotype phasing.
A new animal model developed at WCMC may help investigators develop therapies for anemia of inflammation, a common condition that affects many critically ill patients in intensive care, as well as those with chronic ailments like Crohn’s disease and osteoarthritis.
Hurel, developers of bioanalytic devices used in pharmaceutical development and industrial and consumer product safety testing, announced the introduction of the HµREL® 4-Species Hepatic Cell-Based Assay System – high-functioning, stable, long-enduring primary hepatocyte co-culture plates that enable experimentation in domains not previously susceptible to in vitro methods.
GenVec, a biopharmaceutical company developing gene-delivery technologies for the prevention and treatment of significant health concerns, announced an offering of $9 Million of shares of its common stock to selected institutional investors.
Cornell is one of eight colleges approved to become tax-free zones under Gov. Andrew Cuomo’s Start-Up NY initiative in an effort to spur business and job creation.
A new smartphone app from the Cornell Lab of Ornithology is designed to help people who have never gone bird watching quickly and easily identify a bird by answering a few questions.
Widetronix, makers of millimeter-scale semiconductor chips that convert emitted electrons into electric power, and Cornell University have been awarded $250K each from the New York State Energy Research and Development Authority (NYSERDA) and New York Battery and Energy Storage Technology (NY-BEST) to enhance the power density of their betavoltaic platform.
A new non-invasive urine test developed at Weill Cornell Medical College can distinguish among different causes of acute kidney dysfunction after transplantation. The test may allow patients to avoid invasive kidney biopsies when their transplanted organ is not functioning properly.
Let by Matthew DeLisa, chemical engineers at Cornell have developed a new type of antibody, called a “ubiquibody,” to tag specific proteins inside a cell for destruction, paving the way for new drug therapies and research tools.
Metabolon, a biomedical profiling services company, has entered into an agreement with Human Longevity, Inc. (HLI) to provide metabolomic profiling to assist in HLI’s mission to tackle diseases of aging.
For archived news items, click here.